The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.
Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
Inovio Pharmaceuticals announced a leadership change at the helm and the discontinuation of a Phase III COVID-19 vaccine study.
The U.S. health regulator approved a therapy developed by Johnson & Johnson and the healthcare company’s China-focused partner Legend Biotech Corp. to treat a type of white blood cell cancer.
Takeda and Code Biotherapeutics announced a collaboration agreement to leverage the latter’s proprietary targeted 3DNA non-viral genetic medicine delivery platform for the design and development of gene therapies for rare diseases.
Legend Biotech’s clinical trial of the company’s candidate drug for relapsed or refractory T-cell lymphoma was placed on hold effective February 11 after some issues were raised on the first patient dosed.
The world’s leading COVID-19 vaccine and therapeutic manufacturers continue to develop treatments for the waves of variants as well as life-changing therapies for disease areas outside the world of coronaviruses. The world’s efforts to combat the global pandemic continue to evolve, as does Coronavirus Disease 2019 as variants and subvariants constantly toss volleys of grenades at the battlefront lines.
As a general rule, whatever health condition a person may have, COVID-19 makes it worse. But COVID-19 also causes certain conditions or is being implicated in their earlier onset. Type 1 diabetes and Parkinson’s disease are prime examples. Now, researchers report that the SARS-CoV-2 virus may also cause fetal inflammation, even when the placenta itself is not inflamed.
Aside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
